Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Intermediate AMD: If you have intermediate AMD in one or both eyes, AREDS 2 supplements may help prevent it from turning into late-stage AMD, which causes significant vision loss. Late AMD in One Eye: ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

Glaucoma Treatment MarketThe global glaucoma treatment market, valued at USD 5.7 billion in 2022, is projected to grow at a CAGR of 3.18% during the forecast period, reaching an estimated USD 8.0 ...

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...